Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS.

J Clin Oncol. 2013 Mar 1;31(7):845-52. doi: 10.1200/JCO.2012.43.6097. Epub 2012 Nov 26.

2.

Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck.

Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK.

Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205. doi: 10.1016/j.ijrobp.2012.05.008. Epub 2012 Jun 30.

3.

XRP6258-induced gene expression patterns in head and neck cancer carcinoma.

Yoo GH, Kafri Z, Ensley JF, Lonardo F, Kim H, Folbe AJ, Won J, Stevens T, Lin HS.

Laryngoscope. 2010 Jun;120(6):1114-9. doi: 10.1002/lary.20559.

PMID:
20513026
4.

Intratumoral delivery of docetaxel enhances antitumor activity of Ad-p53 in murine head and neck cancer xenograft model.

Yoo GH, Subramanian G, Ezzat WH, Tulunay OE, Tran VR, Lonardo F, Ensley JF, Kim H, Won J, Stevens T, Zumstein LA, Lin HS.

Am J Otolaryngol. 2010 Mar-Apr;31(2):78-83. doi: 10.1016/j.amjoto.2008.10.002. Epub 2009 Mar 26.

PMID:
20015717
5.

A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group.

Yoo GH, Moon J, Leblanc M, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J, Wolf G.

Arch Otolaryngol Head Neck Surg. 2009 Sep;135(9):869-74. doi: 10.1001/archoto.2009.122.

6.

Effect of docetaxel on the surgical tumor microenvironment of head and neck cancer in murine models.

Yoo GH, Subramanian G, Piechocki MP, Ensley JF, Kucuk O, Tulunay OE, Lonardo F, Kim H, Won J, Stevens T, Lin HS.

Arch Otolaryngol Head Neck Surg. 2008 Jul;134(7):735-42. doi: 10.1001/archotol.134.7.735.

PMID:
18645124
7.

Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709.

Agrawal A, Moon J, Davis RK, Sakr WA, Giri SP, Valentino J, LeBlanc M, Truelson JM, Yoo GH, Ensley JF, Schuller DE; Southwest Oncology Group.

Arch Otolaryngol Head Neck Surg. 2007 Oct;133(10):1044-50.

PMID:
17938330
8.

BMS-275183-induced gene expression patterns in head and neck carcinoma.

Yoo GH, Tran VR, Lemonnier LA, Ezzat WH, Subramanian G, Piechocki MP, Ensley JF, Lonardo F, Kim H, Lin HS.

Am J Otolaryngol. 2007 Sep-Oct;28(5):309-15.

PMID:
17826531
9.

Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.

Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses García A, Raimondi AR, Jufe R, Itoiz M, Gao Y, Saranath D, Kaleebi GS, Yoo GH, Leak L, Myers EM, Shintani S, Wong D, Massey HD, Yeudall WA, Lonardo F, Ensley J, Gutkind JS.

Clin Cancer Res. 2007 Sep 1;13(17):4964-73.

10.

Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study.

Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara DR, Ozer H, Williamson SK, Atkins JN, Schuller DE, Ensley JF.

Cancer Invest. 2007 Apr-May;25(3):182-8.

PMID:
17530488
11.

Benefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell carcinoma of the head and neck.

Shehadeh NJ, Ensley JF, Kucuk O, Black C, Yoo GH, Jacobs J, Lin HS, Heilbrun LK, Smith D, Kim H.

Head Neck. 2006 Dec;28(12):1090-8.

PMID:
16933316
12.

A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.

Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH; Southwest Oncology Group, Head and Neck Working Group.

Cancer. 2006 Jul 15;107(2):319-27.

13.

Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study.

Yoo GH, Lin HS, Iskander AJ, Piechocki MP, Oliver J, Kewson D, Lonardo F, Tainsky MA, Kim HR, Kim H, Ensley JF.

Laryngoscope. 2005 Nov;115(11):1938-46.

PMID:
16319602
14.

Growth factor-sensitive molecular targets identified in primary and metastatic head and neck squamous cell carcinoma using microarray analysis.

Miyazaki H, Patel V, Wang H, Ensley JF, Gutkind JS, Yeudall WA.

Oral Oncol. 2006 Mar;42(3):240-56. Epub 2005 Nov 2.

PMID:
16266819
15.

Uncoupling of epidermal growth factor-dependent proliferation and invasion in a model of squamous carcinoma progression.

Yeudall WA, Miyazaki H, Ensley JF, Cardinali M, Gutkind JS, Patel V.

Oral Oncol. 2005 Aug;41(7):698-708.

PMID:
15935723
16.

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.

Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA; Eastern Cooperative Oncology Group.

J Clin Oncol. 2005 May 20;23(15):3562-7.

PMID:
15908667
17.

An in vivo evaluation of docetaxel delivered intratumorally in head and neck squamous cell carcinoma.

Yoo GH, Subramanian G, Boinpally RR, Iskander A, Shehadeh N, Oliver J, Ezzat W, Piechocki MP, Ensley JF, Lin HS, Shibuya TY, Polin L, Parchment RE.

Arch Otolaryngol Head Neck Surg. 2005 May;131(5):418-29. Erratum in: Arch Otolaryngol Head Neck Surg. 2006 Nov;132(11):1188.

PMID:
15897421
18.

Prognostic significance of G1 cell-cycle inhibitors in early laryngeal cancer.

Korkmaz H, Du W, Yoo GH, Enamorado II, Lin HS, Adsay V, Kewson D, Ensley JF, Shibuya TY, Jacobs JR, Kim H.

Am J Otolaryngol. 2005 Mar-Apr;26(2):77-82.

PMID:
15742257
19.

Spectra of antinuclear antibodies in patients with squamous cell carcinoma of the lung and of the head and neck.

Fernández Madrid F, Karvonen RL, Ensley J, Kraut M, Granda JL, Alansari H, Tang N, Tomkiel JE.

Cancer Detect Prev. 2005;29(1):59-65. Epub 2005 Jan 28.

20.

Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass spectrometry.

Baker H, Patel V, Molinolo AA, Shillitoe EJ, Ensley JF, Yoo GH, Meneses-García A, Myers JN, El-Naggar AK, Gutkind JS, Hancock WS.

Oral Oncol. 2005 Feb;41(2):183-99.

PMID:
15695121
21.

Cellular DNA content parameters as prognostic indicators in human astrocytomas.

El-Rayes BF, Norton CS, Sakr W, Maciorowski Z, Smith D, Pietraszkiewicz H, Del Mar Alonso M, Ensley JF.

J Neurooncol. 2005 Jan;71(2):85-9.

PMID:
15690121
22.

Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial.

Urba SG, Moon J, Giri PG, Adelstein DJ, Hanna E, Yoo GH, Leblanc M, Ensley JF, Schuller DE.

J Clin Oncol. 2005 Jan 1;23(1):88-95.

PMID:
15625363
23.

Correlation of histopathological variants, cellular DNA content, and clinical outcome in adenoid cystic carcinoma of the salivary glands.

Enamorado I, Lakhani R, Korkmaz H, Yoo GH, Del Mar Alonso M, Pietraszkiewicz H, Maciorowski Z, Kim H, Kucuk O, Jacobs JR, Ensley JF.

Otolaryngol Head Neck Surg. 2004 Nov;131(5):646-50.

PMID:
15523442
24.

Pseudoaneuploid subpopulations detected in normal upper aerodigestive tract mucosa consistent with physiological apoptosis in normally differentiating squamous mucosa.

El-Rayes BF, Korkmaz H, Maciorowski Z, Sakr W, Jacobs JR, Ensley JF.

Otolaryngol Head Neck Surg. 2004 Nov;131(5):633-8.

PMID:
15523439
25.

Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer.

Yoo GH, Piechocki MP, Oliver J, Lonardo F, Zumstein L, Lin HS, Kim H, Shibuya TY, Shehadeh N, Ensley JF.

Laryngoscope. 2004 Nov;114(11):1871-9.

PMID:
15510008
26.

Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.

Curino A, Patel V, Nielsen BS, Iskander AJ, Ensley JF, Yoo GH, Holsinger FC, Myers JN, El-Nagaar A, Kellman RM, Shillitoe EJ, Molinolo AA, Gutkind JS, Bugge TH.

Oral Oncol. 2004 Nov;40(10):1026-32.

PMID:
15509494
27.

Microsatellite alterations in african americans with head and neck cancer.

Yoo GH, Nguyen NX, Du W, Schwartz AG, Land S, Lin HS, Kewson D, Murphy LL, Cilluffo D, Ensley JF, Tainsky MA.

Laryngoscope. 2004 Sep;114(9):1619-24.

PMID:
15475792
28.

Cytochrome p450 and glutathione transferase expression in squamous cell cancer.

Ali S, El-Rayes BF, Heilbrun LK, Sarkar FH, Ensley JF, Kucuk O, Philip PA.

Clin Cancer Res. 2004 Jul 1;10(13):4412-6.

29.

Microsatellite analysis of serum DNA in patients with head and neck cancer.

Nawroz-Danish H, Eisenberger CF, Yoo GH, Wu L, Koch W, Black C, Ensley JF, Wei WZ, Sidransky D.

Int J Cancer. 2004 Aug 10;111(1):96-100.

30.

Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup.

N Engl J Med. 2004 May 6;350(19):1937-44.

31.

Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: a case report and review of the literature.

Shehadeh NJ, Vernick J, Lonardo F, Madan SK, Jacobs JR, Yoo GH, Kim HE, Ensley JF.

Am J Otolaryngol. 2004 Jan-Feb;25(1):48-53. Review.

PMID:
15011206
32.

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J.

N Engl J Med. 2003 Nov 27;349(22):2091-8.

33.

Comparison of DNA content parameters in paired, fresh tissue pretreatment biopsies and surgical resections from squamous cell carcinoma of the head and neck.

El-Rayes BF, Maciorowski Z, Pietraszkiewicz H, Ensley JF.

Otolaryngol Head Neck Surg. 2003 Feb;128(2):169-77.

PMID:
12601310
34.

Hormone-refractory prostate cancer responding to capecitabine.

El-Rayes BF, Black CA, Ensley JF.

Urology. 2003 Feb;61(2):462.

PMID:
12597973
35.

Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11.

Weber RS, Berkey BA, Forastiere A, Cooper J, Maor M, Goepfert H, Morrison W, Glisson B, Trotti A, Ridge JA, Chao KS, Peters G, Lee DJ, Leaf A, Ensley J.

Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):44-9.

PMID:
12525193
36.

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.

Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA.

J Clin Oncol. 2003 Jan 1;21(1):92-8.

PMID:
12506176
37.

Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot.

Yoo GH, Piechocki MP, Ensley JF, Nguyen T, Oliver J, Meng H, Kewson D, Shibuya TY, Lonardo F, Tainsky MA.

Clin Cancer Res. 2002 Dec;8(12):3910-21.

38.

Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).

Patel V, Lahusen T, Leethanakul C, Igishi T, Kremer M, Quintanilla-Martinez L, Ensley JF, Sausville EA, Gutkind JS, Senderowicz AM.

Clin Cancer Res. 2002 Nov;8(11):3549-60.

39.

In vivo characteristics of HPV-immortalized and carcinogen transformed oral keratinocytes.

Yoo GH, Piechocki MP, Lonardo F, Meng H, Kewson D, Shibuya TY, Kim H, Stachler R, Ensley JF.

Laryngoscope. 2002 Sep;112(9):1672-9.

PMID:
12352685
40.

Locally advanced nasopharyngeal cancer.

Ensley JF, Youssef E, Kim H, Yoo G.

Curr Treat Options Oncol. 2001 Feb;2(1):15-23. Review.

PMID:
12057137
41.

Laminin-gamma2 overexpression in head-and-neck squamous cell carcinoma.

Patel V, Aldridge K, Ensley JF, Odell E, Boyd A, Jones J, Gutkind JS, Yeudall WA.

Int J Cancer. 2002 Jun 1;99(4):583-8.

42.

Anticancer activity of docetaxel in murine salivary gland carcinoma.

Piechocki MP, Lonardo F, Ensley JF, Nguyen T, Kim H, Yoo GH.

Clin Cancer Res. 2002 Mar;8(3):870-7.

43.

Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.

Tomkiel JE, Alansari H, Tang N, Virgin JB, Yang X, VandeVord P, Karvonen RL, Granda JL, Kraut MJ, Ensley JF, Fernández-Madrid F.

Clin Cancer Res. 2002 Mar;8(3):752-8.

44.

Clinical significance of poor CD3 response in head and neck cancer.

Shibuya TY, Nugyen N, McLaren CE, Li KT, Wei WZ, Kim S, Yoo GH, Rogowski A, Ensley J, Sakr W.

Clin Cancer Res. 2002 Mar;8(3):745-51.

45.

The effects of exogenous p53 overexpression on HPV-immortalized and carcinogen transformed oral keratinocytes.

Yoo GH, Washington J, Oliver J, Piechocki M, Kim H, Foster-Nora J, Shibuya TY, Wilson DR, Ensley JF.

Cancer. 2002 Jan 1;94(1):159-66.

46.

Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study.

Samlowski WE, Gundacker H, Kuebler JP, Giguere JK, Mills GM, Schuller DE, Ensley JF.

Invest New Drugs. 2001;19(4):311-5.

PMID:
11561690
47.

Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer.

Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, Batson E, Reynolds TC, Murray JL.

Clin Cancer Res. 2001 May;7(5):1237-45.

48.

Progression of head and neck cancer in an in vitro model.

Yoo GH, Washington J, Piechocki M, Ensley J, Shibuya T, Oda D, Wei WZ.

Arch Otolaryngol Head Neck Surg. 2000 Nov;126(11):1313-8.

PMID:
11074827
49.
50.

Neutron radiation enhances cisplatin cytotoxicity independently of apoptosis in human head and neck carcinoma cells.

Kim HE, Krug MA, Han I, Ensley J, Yoo GH, Forman JD, Kim HR.

Clin Cancer Res. 2000 Oct;6(10):4142-7.

Supplemental Content

Loading ...
Support Center